News
TEM is a data-rich platform that recently clinched a $200 million deal with AstraZeneca. TEM’s main bet is now on AI for ...
AstraZeneca targets $80bn revenue by 2030, driven by oncology and new drugs, but faces patent risks and tough competition.
President Donald J. Trump just released his second executive order (EO) addressing high prescription drug prices. This is ...
1d
ABC4 Utah on MSNPharmaceutical company AstraZeneca sues Utah Attorney General over discount medication lawThe pharmaceutical company AstraZeneca has filed a federal lawsuit against Utah Attorney General Derek Brown and Utah ...
Pharmaceutical giant AstraZeneca is suing Utah’s attorney general and insurance commissioner over a law passed during the ...
AstraZeneca, a major pharmaceutical company, has sued Utah’s Attorney General Derek Brown over a recently passed state law ...
1d
Zacks Investment Research on MSNWhy Astrazeneca (AZN) is a Top Growth Stock for the Long-TermIt doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...
Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...
The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. | The PD- ...
Artificial intelligence (AI) technologies and machine learning (ML) algorithms are witnessing tremendous growth in immunology ...
Astrazeneca AB has divulged 17β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17β-HSD13) inhibitors reported to be useful for the treatment of alcoholic liver disease, liver fibrosis, cirrhosis, hepatic ...
A ctDNA-guided approach can help identify when patients with HR-positive advanced breast cancer are developing an ESR1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results